Leader of the Neuroimaging group at @barcelonabeta & @fpmaragall /
Associate researcher at @biofinder_study, Lund University #Alzheimer #biomarkers
Gemma Salvad贸
Loading...
Happy to see this massive collaboration out covering 12 different cohorts including almost 3,000 cognitively unimpaired individuals.
Plasma p-tau217 can be used to detect preclinical Alzheimer鈥檚, but positive predictive values increase if +ve results are confirmed with CSF or PET
Super proud of @noellewarmenhoven.bsky.social !
She just nailed her first oral presentation at an international conference #AAIC2025馃嚚馃嚘
Excited to share our review on the latest developments in neuroimaging in #Alzheimer鈥檚 disease .
Great resource to be up to date!
Powerful words from Cliff Jack as he accepted his lifetime achievement award.
We must protect and carry forward our longitudinal cohorts as they are the key to unlocking the mysteries of #Alzheimer鈥檚.
#AAIC2025
If you're at #AAIC2025, don't miss the great work by @wiesjepelkmans.bsky.social !
New paper published today in @nataging.nature.com !
This one took some time but it's always a pleasure working hand in hand with Laia Montoliu-Gaya and the Gothenburg team. Thanks also to the McGill group for also collaborating with TRIAD data.
A 馃У below.
#ENDALZ
Today I will present our work titled: Biological staging of AD with the novel plasma eMTBR-tau243 and %p-tau217
馃Insights into disease trajectory and biological staging of AD (session)
馃晳 2PM
馃搷 Room 105 (even if it's not in the app)
Don't miss it, it will be a great session!
#AAIC2025
馃毃Postdoc position open at @BarcelonaBeta馃毃
We're looking someone to work on a project at the intersection of cardiovascular and neurodegenerative research 馃珋馃
Fully funded position!!!
More details: www.imim.cat/media/upload...
Please share!
#Alzheimer's #ENDALZ
Outstanding plenary presentation by @sylviavilleneuve.bsky.social today on preclinical #Alzheimer鈥檚 disease. Her comprehensive overview of biomarkers, risk factors, and clinical trials highlighted critical directions for the future of AD research.
#AAIC2025
Gemma Salvad贸
A next-generation blood test could personalize Alzheimer's treatment by revealing disease progression鈥攏ot just diagnosis.
BrightFocus Foundation grant recipient, Dr. Gemma Salvad贸, helped validate this test to identify ideal candidates for anti-amyloid therapies.
馃敩 Full story 猬囷笍
